News Sentiment

FHTX sentiment intelligence

Foghorn Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.95 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+12.3% over one week, +42.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Negative

(FHTX) Movement Within Algorithmic Entry Frameworks

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 12.3% Price confirming higher
Trend fit Trend inactive 42.3% over four weeks
Fair value 7.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 36
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 12
www.marketscreener.com 4
TradingKey 4
simplywall.st 4
Finviz 2
TradingView 2
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 19
Analyst action 3
Capital return 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-55 of 55
TradingKey Direct company coverage

Foghorn Therapeutics Inc. (FHTX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Foghorn Therapeutics Inc. (FHTX) by TradingKey, indicating a current valuation score of 8.06 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -3.44 and notes that relevant d

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 18:10
Source
TradingKey
Market source Direct company coverage

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company, announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. Management, including President and CEO Adrian Gottschalk, will present a fireside chat on June 9, 202

Tone
Neutral 50/100
Event
Market update
Published
06 Jun 2026 03:40
Source
Market source
Stock Titan Direct company coverage

Biotech Foghorn CEO to speak at Goldman Sachs global healthcare event

Foghorn Therapeutics (Nasdaq:FHTX) announced that its management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. President and CEO Adrian Gottschalk will lead a fireside chat on June 9, 2026, at 1:20 p.m. EDT, and engage in one-on-one investor

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 11:09
Source
Stock Titan